Pantothenate kinase (PanK) is a metabolic enzyme that is the first and rate-controlling step in the only pathway for cellular coenzyme A (CoA) biosynthesis. A rare, life-threatening neurological disorder known as pantothenate kinase-associated neurodegeneration (PKAN), formerly known as Hallervorden-Spatz disease, arises from mutations in the human PANK2 gene. Here, we studied the neurochemical effects of a drug capable of allosterically activating PanK protein isoforms as a potential PKAN therapeutic. We applied 1HMRS to quantify changes in cerebral metabolites including Glx, GABA, lactate, and NAA in a mouse model of CoA deficiency employing the neuron-specific deletion of Pank1 and Pank2 genes.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords